Back to Journals » Clinical Ophthalmology » Volume 7

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy

Authors Ratanasukon M, Thongthong K, Bhurayanontachai P, Jirarattanasopa P

Received 25 October 2012

Accepted for publication 20 November 2012

Published 10 January 2013 Volume 2013:7 Pages 87—92


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Mansing Ratanasukon, Koblarp Thongthong, Patama Bhurayanontachai, Pichai Jirarattanasopa

Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat yai, Songkhla Province, Thailand

Background: To evaluate photoreceptor disruption in patients with central serous chorioretinopathy (CSC) treated by half-dose photodynamic therapy (PDT).
Methods: A total of 29 patients with symptomatic CSC were recruited and underwent half-dose verteporfin PDT covering the leakage sites as observed via fundus fluorescein angiography. The primary outcome was the percentage of patients with the presence of photoreceptor disruption, and the secondary outcome was the correlation between photoreceptor disruption and visual results at the 1-year follow-up.
Results: Photoreceptor disruption was identified in 13 eyes (44.8%) 12 months after treatment. Twenty-seven patients experienced best-corrected visual acuity (BCVA) improvement after PDT, while two patients showed stable BCVA. The mean BCVA in patients with photoreceptor disruption at the baseline and every follow-up visit was significantly lower than that of patients without photoreceptor disruption. However, there was no correlation between the presence or absence of photoreceptor disruption and the improvement of visual acuity because the BCVA gain at the last follow-up visit between the two groups was not significant (P = 0.69). No potential ocular complication was encountered in the study.
Conclusion: Photoreceptor disruption was found in about 45% of CSC patients treated by PDT, which ultimately resulted in poor visual outcomes. However, a half-dose PDT might not affect or modify the photoreceptor function because it gave the same pattern of visual recovery in patients with and without photoreceptor cell loss.

Keywords: photoreceptor disruption, central serous chorioretinopathy, photodynamic therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma

Donnenfeld ED, Solomon KD, Voskanyan L, Chang DF, Samuelson TW, Ahmed II, Katz LJ

Clinical Ophthalmology 2015, 9:2057-2065

Published Date: 3 November 2015

Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses

Nagahara Y, Koh S, Nishida K, Watanabe H

Clinical Ophthalmology 2015, 9:1029-1031

Published Date: 9 June 2015

Descemet’s stripping and non-Descemet’s stripping automated endothelial keratoplasty for microcornea using 6.0 mm donor grafts

Yokogawa H, Kobayashi A, Yamazaki N, Ueta Y, Hashimoto Y, Tachi N, Sugiyama K

Clinical Ophthalmology 2013, 7:1951-1956

Published Date: 30 September 2013

Intervention with vitamins in patients with nonproliferative diabetic retinopathy: a pilot study

Smolek MK, Notaroberto NF, Jaramillo AG, Pradillo LR

Clinical Ophthalmology 2013, 7:1451-1458

Published Date: 16 July 2013

Lens capsule-related problems in patients undergoing phacoemulsification surgery

Aslan L, Aksoy A, Aslankurt M, Ozdemir M

Clinical Ophthalmology 2013, 7:511-514

Published Date: 9 March 2013

Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment

Houston SK, Shah NV, Decatur C, Lonngi M, Feuer W, Markoe AM, Murray TG

Clinical Ophthalmology 2013, 7:193-198

Published Date: 22 January 2013